Brokerages Set Labcorp Holdings Inc. (NYSE:LH) Target Price at $314.40

Labcorp Holdings Inc. (NYSE:LH) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $314.40.

LH has been the topic of several research analyst reports. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Bank of America boosted their price objective on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Finally, Robert W. Baird boosted their price target on Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a report on Monday, July 13th.

Insider Buying and Selling

In other news, EVP Kathryn W. Kyle sold 92 shares of Labcorp stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $26,329.48. Following the sale, the executive vice president owned 3,904 shares of the company’s stock, valued at approximately $1,117,285.76. The trade was a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Bryan T. Vaughn sold 234 shares of Labcorp stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the transaction, the executive vice president owned 6,746 shares in the company, valued at approximately $1,930,637.74. This trade represents a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 6,991 shares of company stock valued at $1,796,696 in the last quarter. Company insiders own 0.84% of the company’s stock.

Institutional Investors Weigh In On Labcorp

Institutional investors have recently modified their holdings of the stock. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Labcorp during the 4th quarter worth about $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Labcorp during the 4th quarter valued at about $27,000. JPL Wealth Management LLC bought a new position in shares of Labcorp in the 3rd quarter valued at approximately $28,000. Eagle Bay Advisors LLC acquired a new stake in Labcorp in the 4th quarter worth approximately $29,000. Finally, DV Equities LLC acquired a new stake in Labcorp in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Stock Down 0.9%

Shares of NYSE LH opened at $280.86 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. Labcorp has a 1 year low of $241.81 and a 1 year high of $293.72. The stock’s 50-day simple moving average is $266.74 and its 200-day simple moving average is $268.21. The firm has a market cap of $23.03 billion, a price-to-earnings ratio of 24.88, a PEG ratio of 1.88 and a beta of 0.89.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter in the prior year, the business posted $3.84 earnings per share. Labcorp’s revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities analysts anticipate that Labcorp will post 18 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.